← Leaderboards
Ross L Levine
Sloan-Kettering Inst Can Research
$31,715,816
Attributed
$46,500,534
Total exposure
19
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$46,500,534 · 19
By mechanism
R01$15,908,847 · 5
R35$10,340,346 · 1
UG1$5,233,890 · 1
U01$4,779,634 · 2
P01$3,159,792 · 2
U10$2,999,995 · 1
Top collaborators
- Iannis Aifantis20 shared
- Rong Fan11 shared
- Ari M. Melnick7 shared
- Jennifer Jean Trowbridge7 shared
- Franziska Michor6 shared
- Elisabeth Paietta5 shared
- Omar Abdel-Wahab4 shared
- Adolfo A. Ferrando2 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Aaron D Viny$3,272,036
- Mark Thomas Burgess$731,872
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationMolecularSamplingPathogenesisInsightMouse ModelResponseLeukemiaMyeloproliferative DiseaseBaseCellsIn VivoSignal TransductionMutantSomatic MutationEpigenetic ProcessTargeted TreatmentInnovationLaboratoriesHematopoieticProgramsClinical TrialsGeneticGenomics
Grant awards (96)
Synergistic role of signaling and epigenetics in leukemic transformation$1,062,000
R35 · FY2025 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$848,075
UG1 · FY2025 · CA · contact PI
Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation$509,734
U01 · FY2025 · AG
Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis$453,221
P01 · FY2025 · CA · contact PI
Developmental Research Program$235,096
P50 · FY2025 · CA · contact PI
Project 1: Increasing therapeutic efficacy in isocitrate dehydrongenase (IDH)âmutant acute myeloid leukemia (AML)$235,096
P50 · FY2025 · CA · contact PI
Synergistic role of signaling and epigenetics in leukemic transformation$1,008,900
R35 · FY2024 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$848,075
UG1 · FY2024 · CA · contact PI
Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation$523,054
U01 · FY2024 · AG
Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis$430,560
P01 · FY2024 · CA · contact PI
Project 1: Increasing therapeutic efficacy in isocitrate dehydrongenase (IDH)âmutant acute myeloid leukemia (AML)$374,760
P50 · FY2024 · CA · contact PI
Inflammatory Signaling in DNMT3A-Mutated Human Hematopoietic Stem Cells$197,925
U01 · FY2024 · AG
Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation$104,865
U01 · FY2024 · AG
Developmental Research Program$80,397
P50 · FY2024 · CA · contact PI
Synergistic role of signaling and epigenetics in leukemic transformation$1,062,000
R35 · FY2023 · CA · contact PI
Synergistic role of signaling and epigenetics in leukemic transformation$1,056,049
R35 · FY2023 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$892,711
UG1 · FY2023 · CA · contact PI
Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation$515,538
U01 · FY2023 · AG
Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis$470,471
P01 · FY2023 · CA · contact PI
Project 1: Increasing therapeutic efficacy in isocitrate dehydrongenase (IDH)âmutant acute myeloid leukemia (AML)$311,223
P50 · FY2023 · CA · contact PI
Developmental Research Program$16,860
P50 · FY2023 · CA · contact PI
Synergistic role of signaling and epigenetics in leukemic transformation$1,056,049
R35 · FY2022 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$892,711
UG1 · FY2022 · CA · contact PI
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$626,401
R01 · FY2022 · CA · contact PI
Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation$518,079
U01 · FY2022 · AG
Project 1: Increasing therapeutic efficacy in isocitrate dehydrongenase (IDH)âmutant acute myeloid leukemia (AML)$367,707
P50 · FY2022 · CA · contact PI
Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis$354,021
P01 · FY2022 · CA · contact PI
Developmental Research Program$73,344
P50 · FY2022 · CA · contact PI
Synergistic role of signaling and epigenetics in leukemic transformation$1,077,600
R35 · FY2021 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$892,711
UG1 · FY2021 · CA · contact PI
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$639,187
R01 · FY2021 · CA · contact PI
Assessing the Interplay Between Inflammatory Signaling and Epigenetic Dysregulation in Age-associated Clonal Hematopoiesis and Leukemia Initiation$538,000
U01 · FY2021 · AG
The cohesin complex as a tumor suppressor in myeloid leukemia$488,648
R01 · FY2021 · CA
Project 1: Increasing therapeutic efficacy in isocitrate dehydrongenase (IDH)âmutant acute myeloid leukemia (AML)$384,164
P50 · FY2021 · CA · contact PI
Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis$361,246
P01 · FY2021 · CA · contact PI
Developmental Research Program$89,800
P50 · FY2021 · CA · contact PI
Synergistic role of signaling and epigenetics in leukemic transformation$1,028,400
R35 · FY2020 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$859,607
UG1 · FY2020 · CA · contact PI
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$639,187
R01 · FY2020 · CA · contact PI
The cohesin complex as a tumor suppressor in myeloid leukemia$496,859
R01 · FY2020 · CA
Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis$361,246
P01 · FY2020 · CA · contact PI
Synergistic role of signaling and epigenetics in leukemic transformation$932,548
R35 · FY2019 · CA · contact PI
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$620,011
R01 · FY2019 · CA · contact PI
The cohesin complex as a tumor suppressor in myeloid leukemia$489,840
R01 · FY2019 · CA
Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis$350,408
P01 · FY2019 · CA · contact PI
Synergistic role of signaling and epigenetics in leukemic transformation$1,028,400
R35 · FY2018 · CA · contact PI
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$642,416
R01 · FY2018 · CA · contact PI
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2018 · CA
The cohesin complex as a tumor suppressor in myeloid leukemia$511,640
R01 · FY2018 · CA
Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis$378,619
P01 · FY2018 · CA · contact PI
Single-cell cytokine analysis to detect and measure human myelofibrosis$372,267
U01 · FY2018 · DK
Genetic Dissection of Acute Myeloid Leukemia.$355,993
R01 · FY2018 · CA
Synergistic role of signaling and epigenetics in leukemic transformation$1,028,400
R35 · FY2017 · CA · contact PI
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$639,626
R01 · FY2017 · CA · contact PI
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2017 · CA
The cohesin complex as a tumor suppressor in myeloid leukemia$536,993
R01 · FY2017 · CA
Single cell cytokine analysis of circulating malignant hematopoietic cells$394,241
R33 · FY2017 · CA
Single-cell cytokine analysis to detect and measure human myelofibrosis$372,268
U01 · FY2017 · DK
Genetic Dissection of Acute Myeloid Leukemia.$355,993
R01 · FY2017 · CA
Single-cell cytokine analysis to detect and measure human myelofibrosis$3,750
U01 · FY2017 · DK
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$639,626
R01 · FY2016 · CA · contact PI
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2016 · CA
Molecular Pathogenesis and Therapy of ET and PMF$407,075
R01 · FY2016 · CA · contact PI
Single cell cytokine analysis of circulating malignant hematopoietic cells$399,515
R33 · FY2016 · CA
Single-cell cytokine analysis to detect and measure human myelofibrosis$372,268
U01 · FY2016 · DK
Genetic Dissection of Acute Myeloid Leukemia.$355,993
R01 · FY2016 · CA
Single-cell cytokine analysis to detect and measure human myelofibrosis$4,020
U01 · FY2016 · DK
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$639,626
R01 · FY2015 · CA · contact PI
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2015 · CA
Single cell cytokine analysis of circulating malignant hematopoietic cells$421,227
R33 · FY2015 · CA
Single-cell cytokine analysis to detect and measure human myelofibrosis$372,268
U01 · FY2015 · DK
Genetic Dissection of Acute Myeloid Leukemia.$355,993
R01 · FY2015 · CA
Single-cell cytokine analysis to detect and measure human myelofibrosis$3,330
U01 · FY2015 · DK
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$620,436
R01 · FY2014 · CA · contact PI
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2014 · CA
Molecular Pathogenesis and Therapy of ET and PMF$419,296
R01 · FY2014 · CA · contact PI
Genetic Dissection of Acute Myeloid Leukemia.$373,368
R01 · FY2014 · CA
Single-cell cytokine analysis to detect and measure human myelofibrosis$372,268
U01 · FY2014 · DK
Role of TET2 mutations in malignant transformation and acute myeloid leukemia$626,964
R01 · FY2013 · CA · contact PI
Molecular Pathogenesis and Therapy of ET and PMF$406,328
R01 · FY2013 · CA · contact PI
Dynamics of Tumor Stem Cells in Cancer Initiation, Therapy, and Resistance$475,049
R01 · FY2012 · CA
Molecular Pathogenesis and Therapy of ET and PMF$432,264
R01 · FY2012 · CA · contact PI
Dynamics of Tumor Stem Cells in Cancer Initiation, Therapy, and Resistance$487,304
R01 · FY2011 · CA
Molecular Pathogenesis and Therapy of ET and PMF$432,264
R01 · FY2011 · CA · contact PI
Dynamics of Tumor Stem Cells in Cancer Initiation, Therapy, and Resistance$522,904
R01 · FY2010 · CA
Dynamics of Tumor Stem Cells in Cancer Initiation, Therapy, and Resistance$460,217
R01 · FY2010 · CA
Molecular Pathogenesis and Therapy of ET and PMF$198,059
R01 · FY2010 · CA · contact PI
Molecular genetic analysis of tyrosine kinases in myeloproliferative disorders$133,920
K08 · FY2010 · HL · contact PI
Dynamics of Tumor Stem Cells in Cancer Initiation, Therapy, and Resistance$513,998
R01 · FY2009 · CA
Molecular genetic analysis of tyrosine kinases in myeloproliferative disorders$133,920
K08 · FY2009 · HL · contact PI
Dynamics of Tumor Stem Cells in Cancer Initiation, Therapy, and Resistance$499,289
R01 · FY2008 · CA
Molecular genetic analysis of tyrosine kinases in myeloproliferative disorders$133,920
K08 · FY2008 · HL · contact PI
High Throughput Screen for JAK2V617F Mutant Selective Inhibitors$25,000
R03 · FY2008 · DA · contact PI
Molecular genetic analysis of tyrosine kinases in myeloproliferative disorders$125,010
K08 · FY2007 · HL · contact PI
Molecular genetic analysis of tyrosine kinases in myeloproliferative disorders$8,910
K08 · FY2007 · HL · contact PI
Molecular genetic analysis of tyrosine kinases in myeloproliferative disorders$133,920
K08 · FY2006 · HL · contact PI